Key Points
- Mirum Pharmaceuticals CEO Christopher Peetz sold 30,000 shares on June 1 at an average price of $95.84, totaling about $2.88 million, and the sale reduced his direct ownership by 13.37%. The trade was made under a pre-arranged Rule 10b5-1 plan.
- The stock fell 4.3% and opened at $92.17, with a market cap of $5.62 billion. Mirum is trading near its 50-day moving average of $97.01 and has ranged from $43.50 to $114.99 over the past 52 weeks.
- Recent fundamentals and analyst sentiment were mixed but generally positive: Mirum missed EPS expectations in its latest quarterly report, though revenue beat estimates and rose 43.3% year over year. Analysts currently have a consensus rating of “Moderate Buy” with an average target price of $137.64.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) CEO Christopher Peetz sold 30,000 shares of the business's stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the sale, the chief executive officer directly owned 194,309 shares of the company's stock, valued at approximately $18,622,574.56. This trade represents a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christopher Peetz also recently made the following trade(s):
- On Monday, March 16th, Christopher Peetz sold 40,985 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $91.98, for a total transaction of $3,769,800.30.
Mirum Pharmaceuticals Stock Down 4.3%
Shares of NASDAQ MIRM opened at $92.17 on Wednesday. The stock has a market cap of $5.62 billion, a P/E ratio of -6.77 and a beta of 0.50. The firm has a 50 day moving average price of $97.01 and a 200 day moving average price of $89.76. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.99 and a current ratio of 2.09. Mirum Pharmaceuticals, Inc. has a 52-week low of $43.50 and a 52-week high of $114.99.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($12.68). The firm had revenue of $159.88 million for the quarter, compared to analyst estimates of $148.21 million. Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The firm's revenue for the quarter was up 43.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.30) EPS. Analysts expect that Mirum Pharmaceuticals, Inc. will post -2.11 EPS for the current year.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on MIRM shares. Raymond James Financial reiterated a "strong-buy" rating and issued a $165.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Leerink Partners reduced their price target on shares of Mirum Pharmaceuticals from $120.00 to $118.00 and set an "outperform" rating for the company in a report on Thursday, February 26th. TD Cowen upped their price target on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a "buy" rating in a report on Thursday, May 7th. Evercore reiterated an "outperform" rating and issued a $138.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Finally, Wolfe Research started coverage on shares of Mirum Pharmaceuticals in a report on Tuesday, May 19th. They issued an "outperform" rating and a $145.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $137.64.
Read Our Latest Stock Report on MIRM
Institutional Trading of Mirum Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the business. Faithward Advisors LLC lifted its position in shares of Mirum Pharmaceuticals by 0.5% in the first quarter. Faithward Advisors LLC now owns 27,467 shares of the company's stock worth $2,537,000 after purchasing an additional 126 shares in the last quarter. MCF Advisors LLC lifted its position in shares of Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company's stock worth $31,000 after purchasing an additional 185 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in shares of Mirum Pharmaceuticals by 6.7% in the fourth quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company's stock worth $253,000 after purchasing an additional 200 shares in the last quarter. Jones Financial Companies Lllp lifted its position in shares of Mirum Pharmaceuticals by 34.0% in the third quarter. Jones Financial Companies Lllp now owns 957 shares of the company's stock worth $70,000 after purchasing an additional 243 shares in the last quarter. Finally, Arizona State Retirement System lifted its position in shares of Mirum Pharmaceuticals by 2.6% in the third quarter. Arizona State Retirement System now owns 10,984 shares of the company's stock worth $805,000 after purchasing an additional 275 shares in the last quarter.
About Mirum Pharmaceuticals
(
Get Free Report)
Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.
Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
